

Arkansas Medicaid PAD Subcommittee Meeting Minutes

Date / Time:		December 8, 2025 2:00-4:00 PM Central	Location:		Teams webinar
Chair:		Cindi Pearson, Pharm.D.	Reports:		Brooke Owens, Pharm.D. Prime Therapeutics
Attendance		Panelist (voting members)		Panelist (non-voting members)	Organization
	X	Ashley Crawley, Pharm.D.	X	Barry Fielder, Pharm.D.	ATC
		Gabriella Douglass, Pharm.D.	X	Lora Ertmoed, Pharm.D.	Empower
	X	William Golden, M.D.	X	Lauren Jimerson, Pharm.D.	Summit
	X	Melissa Max, Pharm.D.	X	Jessica Lawson, Pharm.D.	CareSource
		Open M.D. position	X	Ifeyinwa Onowu, Pharm.D.	CareSource
		Panelist (non-voting) Prime Therapeutics	X	Cindi Pearson, Pharm.D.	DHS, DUR Chair
		Karen Evans, P.D.	X	Cynthia Neuhofel, Pharm.D.	DHS pharmacy
	X	Jeniffer Martin, Pharm.D.		Elizabeth Pitman, J.D.	DHS DMS director
	X	Lesley Irons, Pharm.D.		Christopher Smith, M.D.	DHS advisor
	X	Linsey Gillam, Pharm.D.	X	Shane David, Pharm.D.	ADH advisor
	X	Alyson Greenwood, Pharm.D.			
	X	Brooke Owens, Pharm.D.			
	X	Allison Sweeney, Pharm.D.			
	Call to order		Meeting held virtually by Teams webinar. A quorum was present, and the chair called the meeting to order at 2:02pm. No members had any conflicts of interest on agenda items.		
Public Comments		No public speakers			
Announcements		<ul style="list-style-type: none">• Introduction of Brooke Owens, Pharm.D. who is the physician administered drug pharmacist with Prime Therapeutics• Subcommittee member expectations• Dr. Douglass could not attend this meeting. She reviewed the materials ahead of the meeting for input via Dr. Pearson as her proxy. Dr. Douglass’ comments—”I reviewed the monographs and the full packet, and I do not have any concerns at this time. Please keep me on the distribution list for all materials, calendar holds, and follow-up communications.”• Per legal interpretation of federal regulations and the current DUR Board Bylaws, the Subcommittee’s review and recommendations must be sent to the DUR Board during the following meeting for final vote prior to posting the criteria/monographs online.			
Minutes		None			
Discussion		<ul style="list-style-type: none">• Subcommittee members discussed the meeting cadence going forward and decided on the 2nd Wednesday of March, June, September, and December from 12-1pm CST.• Dr. Crawley stated she had not received the monographs. Dr. Pearson resent them. Dr. Crawley asked if we could bring a topic back to the subcommittee if a concern was identified. Dr. Pearson stated that members could submit review requests to her, and we would add the topic to the next agenda.• Dr. Pearson discussed potentially creating a PAD oncology policy. After little discussion from the Subcommittee, it was determined to develop monograph/criteria for oncology medications like any other PAD. No policy will be developed at this time.			
Monographs		Dr. Pearson provided a history of the PAD monograph review process. Dr. Golden gave more context to the rationale for the current process. Dr. Pearson sent the Subcommittee members the monographs for review on November 24 th and December 5 th . Dr. Pearson discussed the fact that some medications are available as both medical claims and pharmacy claims, and that it will take some time to ensure consistency between medical and pharmacy criteria. The Chair asked for a vote for approval of the current medical director approved monographs. Dr. Golden made the motion to approve the document of the measures as a consent calendar which would allow for extraction of specific topics for further discussion at a later time. Dr. Max seconded the motion. All voting members voted for the motion, and motion passed.			
Board comments		Dr. Neuhofel stated that the Prime Therapeutics website has a designated tab for PAD information, and Dr. Pearson shared her screen with the website information.			
Adjourn		Meeting was adjourned at 2:28pm.			